The Prescrire Awards for 2019
The Prescrire Drug Awards for 2019
The Prescrire Drug Awards for 2019
|
Three drugs made the Honours List and three others were recognised as Noteworthy, but there was no "Pilule d'Or" ("Golden Pill") awarded this year. |
Three drugs were placed on the "Honours List", since they were found to constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations:
- HEMLIBRA° (emicizumab) Roche
Prophylaxis of bleeding episodes in patients with haemophilia A and "factor VIII inhibitors"
- KYMRIAH° (tisagenlecleucel) Novartis
B-cell acute lymphoblastic leukaemia in children and young adults when other treatment options have been exhausted
- YESCARTA° (axicabtagene ciloleucel) Kite Pharma (a Gilead company)
Certain types of large B-cell lymphomas when other treatment options have been exhausted
Drugs that were deemed "Noteworthy" provide a modest improvement in patient care:
- JAKAVI° (ruxolitinib) Novartis
Symptomatic myelofibrosis
- KADCYLA° (trastuzumab emtansine) Roche
HER2-positive inoperable breast cancer in women who previously received trastuzumab and a taxane
- KEYTRUDA° (pembrolizumab) MSD
Metastatic non-small cell lung cancer, as first-line treatment
For details, download the complete review: |
FREE "The Prescrire Awards for 2019" Prescrire Int 2020; 29 (213): 77-81. (Pdf, free)
> Rules governing the Prescrire Awards (pdf, in French)
Back to the contents page for the 2019 Prescrire Awards >
©Prescrire 1 February 2020 |
Share |
|
|
|